<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03134157</url>
  </required_header>
  <id_info>
    <org_study_id>Royan-Emb-029</org_study_id>
    <nct_id>NCT03134157</nct_id>
  </id_info>
  <brief_title>The Effect of Simvastatin on Uterine Leiomyoma Development and Growth in Infertile Women</brief_title>
  <official_title>Evaluation the Effect of Simvastatin on Uterine Leiomyoma Development and Growth in Infertile Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royan Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Royan Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Uterine leiomyomas with an estimated incidence of 50%-80% are the most common tumors of
      female reproductive system. Statins as a HMG-CoA reductase inhibitors inhibit the mevalonate
      pathway of cholesterol synthesis, thus have been known as a group of drugs used for treatment
      of hypercholesterolemia. Statins inhibit proliferation of several cell types including
      vascular smooth muscle, hepatocytes and other cell types. Leiomyomas are benign uterine
      tumors characterized by smooth muscle proliferation and excessive deposition of extracellular
      matrix. In the present study we aim to evaluate the effect of simvastatin on uterine
      leiomyoma development and growth.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposal of the present study approved by our institutional review boards and
      institution's ethical committee, and all participants will sign a written consent before
      enter to study. All patients will be randomly divided into three groups and will be
      randomized to receive simvastatin 40 mg orally + vaginal placebo, simvastatin 40 mg vaginally
      + oral placebo and vaginal placebo + oral placebo for 3 months.

      CBC, Lipid profile, kidney &amp; Liver function tests, FBS &amp; hormonal evaluation will be
      performed before and after the treatment. Ultrasound examination will be performed before and
      after the treatment for determining of the number, size, and site of the myoma and also size
      of the uterus.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2016</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Uterine fibroid size</measure>
    <time_frame>3 months</time_frame>
    <description>Evaluation the size of Uterine fibroid withultrasound.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Uterine size</measure>
    <time_frame>3months</time_frame>
    <description>Evaluation the uterine size with ultrasound.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of Vitamin D3</measure>
    <time_frame>3 months</time_frame>
    <description>Evaluation the Plasma concentration of Vitamin D3 with blood sampling.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Simvastatin and vaginal placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients with leiomyoma receive simvastatin 40 mg orally+ vaginal placebo will be given every day for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Simvastatin and oral placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients with leiomyoma receive simvastatin 40 mg orally+ oral placebo will be given every day for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaginal placebo+ oral placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients with leiomyoma receive Vaginal placebo+ oral placebo every day for 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral drug and vaginal placebo</intervention_name>
    <description>prescription of simvastatin 40 mg orally+ vaginal placebo every day for 3 months.</description>
    <arm_group_label>Simvastatin and vaginal placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral drug and oral placebo</intervention_name>
    <description>prescription of simvastatin 40 mg orally+ oral placebo every day for 3 months.</description>
    <arm_group_label>Simvastatin and oral placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vaginal placebo+ oral placebo</intervention_name>
    <description>prescription of Vaginal placebo + oral placebo every day for 3 months.</description>
    <arm_group_label>Vaginal placebo+ oral placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 20-40 years

          -  Intramural Fibroids confirmed by ultrasound

          -  Presence of at least one fibroid with size &gt;4 cm or two fibroids with size &gt;3 cm
             detected by pelvic ultrasound.

          -  Presence of at least 3 fibroids with size &lt;3 cm and a history of 2 IVF failures.

          -  Number of fibroids ≤ 5

          -  BMI&gt;25 Kg/m2

        Exclusion Criteria:

          -  Pregnancy

          -  Hormonal contraception or any hormonal therapy received in the last 3 months

          -  Alcohol consumption

          -  Allergic to simvastatin

          -  Suspicion or diagnosis of cancer

          -  Signs or symptoms of mental illness, hepatic dysfunction, myopathic syndromes,
             diabetes mellitus, renal disease, Cardiovascular disease, hypothyroidism, hypotension,
             neuropathy, lupus and cataract

          -  Hb ≤ 7

          -  Taking antifungal medications, Lipid-Lowering medications (gemfibrozil, clofibrate),
             warfarin, danazol and erythromycin in the last one month.

          -  Severe male factor

          -  Severe endometriosis

          -  Diminished ovarian reserve
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mahnaz Ashrafi, MD</last_name>
    <role>Study Director</role>
    <affiliation>) Endocrinology and Female Infertility Department, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hamid Gourabi, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Head of Royan Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Firoozeh Ahmadi, MD</last_name>
    <role>Study Director</role>
    <affiliation>) Endocrinology and Female Infertility Department, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nadia Jahangiri, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>) Endocrinology and Female Infertility Department, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nasser Aghdami, MD,PhD</last_name>
    <phone>(+98)23562000</phone>
    <phone_ext>516</phone_ext>
    <email>nasser.aghdami@royaninstitute.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Leila Arab, MD</last_name>
    <phone>(+98)23562000</phone>
    <phone_ext>414</phone_ext>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royan Institute</name>
      <address>
        <city>Tehrān</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nasser Aghdami, MD,PhD</last_name>
      <phone>(+98)2123562000</phone>
      <phone_ext>516</phone_ext>
      <email>nasser.aghdami@royaninstitute.org</email>
    </contact>
    <contact_backup>
      <last_name>Leila Arab, MD</last_name>
      <phone>(+98)2123562000</phone>
      <phone_ext>414</phone_ext>
      <email>Leara91@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Firoozeh Ghafari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elham Amirchaghmaghi, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Farnaz Akbari, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amir Almasi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2017</study_first_submitted>
  <study_first_submitted_qc>April 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2017</study_first_posted>
  <last_update_submitted>April 26, 2017</last_update_submitted>
  <last_update_submitted_qc>April 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Leiomyoma simvastatin infertility</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

